Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 6 months later Dec 30, 2025 → Jun 30, 2027
See other at-risk trials from Herrick Medical LLC

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 30, 2025 to Jun 30, 2027
    • Primary endpoints: details revised at 1 of 4 entries
    • Study completion pushed from Sep 30, 2026 to Sep 30, 2027
    • Eligibility criteria expanded, about 20 words
  2. Trial status: Active, Not Recruiting to Recruitingv7 Show 7 more changesShow less
    • Enrollment target: 7 to 40
    • Primary completion date: Dec 30, 2024 to Dec 30, 2025
    • Study completion date: Sep 30, 2025 to Sep 30, 2026
    • Interventions: ECHS AD Device (Device), ECHS Sham AD Device (Device) to ECHS AD Device (Device)
    • Eligibility criteria shortened, about 24 words
    • Site details revised
    • Study arms: 2 to 1
  3. Enrollment target: 24 to 7v6 Show 4 more changesShow less
    • Primary completion date: Dec 30, 2023 to Dec 30, 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 30, 2024 to Sep 30, 2025
    • Site details revised
  4. Lead sponsor: [Redacted] to Herrick Medical LLCv5 Show 6 more changesShow less
    • Trial status: Withheld to Recruiting
    • Primary completion date: Dec 30, 2023
    • Study completion date: Sep 30, 2024
    • Start date: May 1, 2023
    • Collaborators expanded, about 3 words
    • Study title shortened, about 4 words
  5. 3 versions Re-verified since Aug 1, 2022, no change to tracked fieldsv2-v4
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days. Primary end points are the The Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Mini-Mental State Exam. Participants will be followed-up for 9 months post-treatment.
Trial Details
NCT Number NCT05295615
Lead Sponsor Herrick Medical LLC
Collaborators: Hackensack Meridian Health
Conditions
(from sponsor)		 Alzheimer Disease
Related terms Alzheimer Disease
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov